Sponsored by
Food and Drug Administration officials say they would like a stronger warning for contrasting agents used to make MRI scans easier to see. The "black box" warning would inform physicians that patients with certain kidney and liver conditions are at risk for a potentially fatal skin disease called nephrogenic systemic fibrosis (NSF).